S-1/A: Therapeutic Solutions International Files Amendment for $9.2 Million Common Stock Offering

Therapeutic Solutions International amends its S-1 registration statement to facilitate the sale of up to 300 million shares of common stock by a selling shareholder, potentially raising $9.2 million for working capital.

Summary

• Therapeutic Solutions International (TSOI) has filed an amendment to its Form S-1 registration statement.
• The amendment pertains to the sale of up to 300,000,000 shares of common stock by a selling shareholder.
• TSOI may receive aggregate gross proceeds of up to $9,219,567.99 from the sale of common stock to GHS Investments, LLC, the selling shareholder, under a securities purchase agreement.
• The proceeds will be used for working capital purposes.
• GHS Investments, LLC, is considered an underwriter, and any broker-dealers involved may also be deemed underwriters.
• TSOI will bear the costs of registration, while the selling shareholder will cover commissions and discounts.
• The common stock is quoted on the OTC Markets under the symbol TSOI, with the last reported sale price on January 30, 2024, at $0.00105 per share.
• The company's independent registered public accounting firm has included a going concern paragraph regarding its consolidated financial statements.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to the potential capital raise being offset by the going concern warning and the identified material weaknesses in internal control.

Positives

• Potential influx of $9.2 million in working capital if all shares are sold to GHS Investments, LLC.
• The company has a large portfolio of immunotherapies that range from dendritic cell vaccines for cancers to Parkinsons Disease developed on our StemVacs platform.
• The company has transferred ownership of the IND titled Treatment of Metastatic Breast Cancer by StemVacs-V Cancer Immunotherapeutic to Res Nova Bio with the primary objective being safety and feasibility of StemVacs-V administration at 12 months as assessed by lack of adverse medical events.

Negatives

• The company's auditor has raised concerns about its ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's liquidity and capital resources are very limited.
• The company will require significant additional external financing to implement its business plan.
• The company may not be able to effectively manage its potential growth and the execution of its business plan.

Risks

• The company has identified material weaknesses in its internal control over financial reporting.
• The company's liquidity and capital resources are very limited.
• The company will require significant additional external financing to implement its business plan.
• The company may not be able to effectively manage its potential growth and the execution of its business plan.
• The company faces significant competition for its products.
• Government regulation could adversely affect the company's business.
• The company's success may depend upon its ability to protect its patents and proprietary technology.
• Third parties may claim that the company is infringing their intellectual property.
• The company may be subject to claims brought against it as a result of product liability claims.
• The company may be subject to claims brought against it as a result of product associated content it provides.
• Changes in commodity and other operating costs or supply chain and business disruptions could adversely affect the company's results of operations.
• The company faces substantial competition in attracting and retaining qualified senior management and key personnel.

Future Outlook

The company intends to finance operating costs over the next twelve months through its existing financial resources and may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements.

Industry Context

The announcement reflects a common financing strategy for small-cap companies, particularly in the biotechnology sector, to raise capital through equity offerings. The reliance on a selling shareholder and the OTC Markets listing indicate the company's current stage of development and access to capital markets.

Comparison to Industry Standards

• It's difficult to directly compare TSOI's financial situation to industry standards without specific financial data within the document.
• However, the going concern warning from the auditor is a significant concern and suggests the company is underperforming compared to more financially stable peers.
• The reliance on OTC Markets for trading is typical for companies with limited market capitalization, but it also implies higher volatility and lower liquidity compared to companies listed on major exchanges like NASDAQ or NYSE.
• Comparable companies in the regenerative medicine and nutraceutical space often seek partnerships or licensing agreements to validate their technology and generate revenue, which TSOI is also pursuing.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's ability to execute its business plan and address financial concerns will impact employees and other stakeholders.

Next Steps

• The selling shareholder will proceed with the sale of common stock.
• TSOI will use the proceeds for working capital.
• TSOI needs to address the going concern issue and material weaknesses in internal control.

Key Dates

Keywords

common stock, Therapeutic Solutions International, GHS Investments, offering, securities purchase agreement, working capital, OTC Markets, TSOI, shares, registration statement